Denali Therapeutics (NASDAQ: DNLI) net income
Denali Therapeutics reported a net loss of $512.5m for fiscal 2025; in fiscal 2024 it reported a net loss of $422.8m. Earnings per share were −$2.97.
Denali Therapeutics's best year of the last 9 was fiscal 2020. It reported a loss in 8 of those 9 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$512.5m | — | — | −$2.97 |
| 2024 | −$422.8m | — | — | −$2.57 |
| 2023 | −$145.2m | — | −43.9% | −$1.06 |
| 2022 | −$326.0m | — | −300.6% | −$2.60 |
| 2021 | −$290.6m | −508.5% | −597.2% | −$2.39 |
| 2020 | $71.1m | — | 21.2% | $0.65 |
| 2019 | −$197.6m | — | −740.7% | −$2.07 |
| 2018 | −$36.2m | — | −28.1% | −$0.39 |
| 2017 | −$88.2m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Denali Therapeutics net income compared with its sector
By net income for its latest fiscal year, Denali Therapeutics ranks 474th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 472nd | Dyne Therapeutics | −$446.2m | — |
| 473rd | Immunovant | −$505.6m | — |
| 474th | Denali Therapeutics | −$512.5m | — |
| 475th | Integra Lifesciences | −$516.5m | −31.6% |
| 476th | Avantor | −$530.2m | −8.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Denali Therapeutics
- How much did Denali Therapeutics earn in fiscal 2025?
- Denali Therapeutics reported a net loss of $512.5m for fiscal 2025. In fiscal 2024 it reported a net loss of $422.8m.
- What are the earnings per share of Denali Therapeutics?
- They were −$2.97 in fiscal 2025, compared with −$2.57 in fiscal 2024.
- What was the most profitable year for Denali Therapeutics?
- Of its last 9 fiscal years, fiscal 2020, with $71.1m.
- Where does Denali Therapeutics rank in its sector by net income?
- It ranks 474th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Denali Therapeutics come from?
- From the annual report (Form 10-K) that Denali Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Denali Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on Denali Therapeutics: the Denali Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.